Center-Authored Papers

Filters: Author is Jagannath, Sundar  [Clear All Filters]
2013
Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S et al..  2013.  A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
2012
Bensinger WI, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS, Ewald B, Bilic S, Rediske J, Baeck J et al..  2012.  A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology. :n/a-n/a.
2011
Munshi NC, Anderson KC, Bergsagel LP, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart KA, Harousseau J-L, Dimopoulos M et al..  2011.  Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.. Blood. 117(18):4696-700. Abstract
Cavo M, Rajkumar VS, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M et al..  2011.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.. Blood. 117(23):6063-73. Abstract
2010
Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH et al..  2010.  Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.. British journal of haematology. 148(4):562-8. Abstract
2009
Jagannath S, Durie BGM, Wolf JL, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A et al..  2009.  Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.. British journal of haematology. 146(6):619-26. Abstract
Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger WI, Badros AZ, Vescio R et al..  2009.  Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.. Blood. 114(4):772-8. Abstract